HOME >> BIOLOGY >> NEWS
Brookhaven scientists determine key Lyme disease protein structure

UPTON, NY A research team working at the U.S. Department of Energys Brookhaven National Laboratory has determined the three-dimensional structure of a key protein on the bacterium that causes Lyme disease. Called OspC, the protein is derived from two strains of the Lyme disease bacterium. This research may lead to a second-generation vaccine that would be more effective than the current one.

The current vaccine is based on another Lyme disease protein, known as OspA, which was previously deciphered at Brookhaven. Both OspA and OspC are outer surface proteins of Borrelia burgdoferi, the bacterium that causes Lyme disease. Researchers from Brookhaven Lab, Stony Brook Universitys School of Medicine, the University of Rochester Medical Center and Rutgers University will report their findings on the structure of OspC in the March 1, 2001 edition of The EMBO Journal.

Spread by the bite of an infected deer tick, Lyme disease is the most common vector-borne disease in the U.S. Between 1982 and 1996, more than 99,000 cases were reported in the nation. Early symptoms of the disease include a bulls-eye rash and flu-like symptoms. If the disease is not promptly treated with antibiotics, more serious symptoms, including joint and neurological complications, may develop.

To determine the structure of OspC, the researchers used a technique at Brookhavens National Synchrotron Light Source (NSLS) known as multiple wavelength anomalous diffraction. First, researchers grew crystals of the protein that could withstand the intense x-rays at the NSLS. To make large quantities of OspC, the team used the T7 gene-expression system, which was developed at Brookhaven.

Then the crystal was illuminated with beams of x-rays at different energies, and diffraction patterns were recorded on a detector. With the aid of powerful computers, the researchers then analyzed the diffraction patterns to gain the vital information needed to create an image of the protein
'"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
27-Feb-2001


Page: 1 2

Related biology news :

1. Brookhaven lab biophysicist F. William Studier wins R&D 100 award
2. Workshop for new synchrotron light source at Brookhaven
3. Brookhaven Lab expects $30 million to support life sciences
4. Brookhaven Lab develops ThraxVac to clean up anthrax
5. Brookhaven Lab & Battelle collaborate on research that may lead to novel anti-microbial drugs
6. Rice, Brookhaven physicists decode initial stage of cell fusion
7. Brookhaven Lab scientist wins Environmental Mutagen Society Award
8. Brookhaven Spotlights: News from the National Synchrotron Light Source
9. Enzyme studies at Brookhaven Lab may lead to new antiviral agents
10. New Brookhaven Lab study shows how ritalin works
11. New test for radiation damage to DNA developed at Brookhaven Lab

Post Your Comments:
(Date:4/17/2014)... hundred births, Down syndrome - or trisomy 21 - ... It results from a chromosomal abnormality where cells of ... (1% of the human genome). A study conducted by ... Genetic Medicine and Development at the University of Geneva ... shed light on how the extra chromosome 21 upsets ...
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
(Date:4/17/2014)... channels are implicated in many serious conditions such as ... potential target for drug therapies. Unfortunately, there is still ... Cambridge research provides fresh and unexpected insight into the ... components - β-subunit molecules - which are responsible for ... published in the most recent edition of the ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
Cached News: